Study Stopped
The primary endpoint was not met on the double blind data
Efficacy and Safety Study to Treat Subjects With Symptomatic Internal Hemorrhoids
VEN309
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Treatment Group, Multicenter Efficacy and Safety Study of Intra-Anal Application of Iferanserin (10 mg) as a 0.5% Ointment in Subjects With Symptomatic Internal Hemorrhoids
1 other identifier
interventional
403
1 country
77
Brief Summary
Primary Objective: To evaluate the effect of iferanserin ointment on cessation of bleeding when administered intra-anally twice daily (BID) for 7 or 14 days in subjects with symptomatic internal hemorrhoids. Methodology: Double-Blind: Phase 3, multicenter, double-blind, randomized, parallel group, placebo-controlled part of the study. Extension: Multicenter, open-label part of the study. Study Treatment Duration: Double-Blind: 28 days (14-day treatment period and a 14-day follow-up period). Extension: 12 months (open-label part of the study in which there will be a scheduled visit every three months. Subjects who have recurrence(s) of their symptomatic internal hemorrhoids will be treated with open-label iferanserin for 7 days followed by a 21-day follow-up period). Criteria for Evaluation: Primary Endpoint: The primary endpoint is the cessation of bleeding by the end of Day 7 that persists for the remainder of the treatment period (through Day 14).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Jul 2011
Shorter than P25 for phase_3
77 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 16, 2011
CompletedFirst Posted
Study publicly available on registry
May 18, 2011
CompletedStudy Start
First participant enrolled
July 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2012
CompletedJanuary 28, 2014
July 1, 2012
11 months
May 16, 2011
January 26, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Proportion of subjects with cessation of bleeding by the end of Day 7 that persists for the remainder of the treatment period (through Day 14) will be analyzed as the primary endpoint
7 days
Secondary Outcomes (1)
Proportion of subjects with cessation of pain by the end of Day 7 that persists for the remainder of the treatment period (through Day 14).
7 days
Study Arms (3)
Iferanserin
EXPERIMENTALPlacebo
EXPERIMENTALIferanserin + Placebo
EXPERIMENTALInterventions
0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 14 days during double blind.
0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 7 days followed by placebo ointment BID for 7 days during the double blind.
Eligibility Criteria
You may qualify if:
- Males or non-pregnant females, aged ≥ 18 to ≤ 75 years.
- Symptomatic internal hemorrhoids, Grades I-III by direct anoscopic visualization (anoscopic visualization not required if Grade determined by colonoscopy within 28 days prior to Day 1).
- Bleeding from hemorrhoids for two consecutive days prior to randomization (Day 1).
- Itching OR pain for two consecutive days prior to randomization (Day 1).
- Able to attempt bowel movements daily (defined as trying to have a bowel movement while sitting on the toilet for at least a few minutes, at least once daily, whether or not you feel the need to have a bowel movement that day).
- Body mass index of ≥ 18.5 to ≤ 36 kg/m2.
- Female of non-childbearing potential, including any female who: a) has had a hysterectomy, b) has had a bilateral oophorectomy, c) has had a bilateral tubal ligation or d) is post menopausal (demonstration of total cessation of menses for ≥ 1 year from the date of the screening visit).
- Females of child bearing potential who agree to use two forms of contraception, one of which must be a barrier method, during the full duration of the study.
- Able to communicate adequately with the investigator and to comply with the requirements for the entire study.
- Capable of using the IVRS and adequately communicate comprehension of IVRS questions to the investigator.
- Capable of and freely willing to provide written informed consent prior to participating in the study.
You may not qualify if:
- Grade IV internal hemorrhoids.
- Age ≥ 40 years, with no complete colon evaluation within three years.
- Age \< 40 years, with no sigmoidoscopy or complete colon evaluation within three years.
- Age \< 40 years, with any of the following and no complete colon evaluation within two years; or age ≥ 40 years, with any of the following and no complete colon evaluation within one year:
- History of adenomatous polyps.
- Family history of either colorectal cancer or colorectal adenomas diagnosed in a first-degree relative before age 60.
- Family history or genetic testing indicating the presence of one of two hereditary syndromes.
- Malignancy within 5 years prior to Day 1(with the exception of treated basal cell/squamous cell carcinoma of the skin).
- History of inflammatory bowel disease.
- History of irritable bowel syndrome with constipation or diarrhea.
- Previous surgical or instrumental treatment of internal hemorrhoids.
- Clinical evidence or history of fecal incontinence.
- Current thrombosed internal or external hemorrhoid(s).
- Clinical evidence or history of anal fissure.
- Clinical evidence or history of anal fistula.
- +34 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (77)
Digestive Health
Dothan, Alabama, United States
Clinical Research Associates
Huntsville, Alabama, United States
Comprehensive Health Services
Phoenix, Arizona, United States
Adobe
Tucson, Arizona, United States
Desert Sun Clin Res
Tucson, Arizona, United States
AR Gastro
Sherwood, Arkansas, United States
ACRI
Anaheim, California, United States
Providence Clin Res
Burbank, California, United States
Med Center
Carmichael, California, United States
South Orange County Surgical Group
Laguna Hills, California, United States
Torrence C. R.
Lomita, California, United States
Premiere Clin Res
Long Beach, California, United States
Facey Med Foundation
Mission Hills, California, United States
Futura Research
Montebello, California, United States
Community Clin Trials
Orange, California, United States
Del Carmen Med Center
Reseda, California, United States
MARG
San Diego, California, United States
Med Center for Clinical Research
San Diego, California, United States
Westlake Res
Westlake Village, California, United States
Colorado Research
Salida, Colorado, United States
Innovative
Clearwater, Florida, United States
Avail Clin Res
DeLand, Florida, United States
Eastern
Hilieah, Florida, United States
Center for GI Disorders
Hollywood, Florida, United States
Nature Coast Clin Res
Inverness, Florida, United States
Jupiter Research
Jupiter, Florida, United States
Aplusresearch
Miami, Florida, United States
Kendall
Miami, Florida, United States
MRA
Miami, Florida, United States
Advanced Gastro Assoc
Palm Harbor, Florida, United States
ICR
Sanford, Florida, United States
Cleveland Clinic Florida
Weston, Florida, United States
Southeast REgional Research Group
Columbus, Georgia, United States
Tri County
Hartwell, Georgia, United States
Southeast Regional Research Group
Savannah, Georgia, United States
Pinnacle Med Inst
Overland, Kansas, United States
Kentucy med Center
Lexington, Kentucky, United States
Praetorian Pharmaceutical Res
Marrerro, Louisiana, United States
Clinical Trials Mgmt
Metarie, Louisiana, United States
Delta Research
Monroe, Louisiana, United States
Women Under Study
New Orleans, Louisiana, United States
Capital Digestive
Chevy Chase, Maryland, United States
Meritus Center for Clin Res
Hagerstown, Maryland, United States
Mid Atlantic Res Center
Hollywood, Maryland, United States
Saginaw Med Res
Saginaw, Michigan, United States
Gastro Assoc Western Michigan
Wyoming, Michigan, United States
Gastrointestinal Associates
Jackson, Mississippi, United States
Midwest Center for Clin Res
Lee's Summitt, Missouri, United States
Center for Digestive & Liver Diseases
Mexico, Missouri, United States
Clin Res Nevada
Las Vegas, Nevada, United States
S. Jersey Gastro
Marlton, New Jersey, United States
Long Island GI Group
Great Neck, New York, United States
MRA NY
New York, New York, United States
Ashville Gastro
Asheville, North Carolina, United States
Carolinas Res Ass
Davidson, North Carolina, United States
Vital
Greenboro, North Carolina, United States
Carolinas Research
Harrisburg, North Carolina, United States
Wake Res
Raleigh, North Carolina, United States
Trial Management Associates
Wilmington, North Carolina, United States
Hightop Med Res
Cincinnati, Ohio, United States
Dayton Gastro
Dayton, Ohio, United States
Great Lakes Gastro
Mentor, Ohio, United States
Central Sooner
Norman, Oklahoma, United States
Clinsearch
Chattanooga, Tennessee, United States
Memphis Gastro
Germantown, Tennessee, United States
Assoc of Gastro
Hermitage, Tennessee, United States
Dial Research
Nashville, Tennessee, United States
First Clinic
Nashville, Tennessee, United States
Texas Health Research
Fort Worth, Texas, United States
Amcare Research
Houston, Texas, United States
Houston Gastro
Houston, Texas, United States
Permian
Odessa, Texas, United States
Pioneer Research
Sugarland, Texas, United States
ARI
Ogden, Utah, United States
ARI
Sandy City, Utah, United States
New River Valley Res
Christianburg, Virginia, United States
Blue Ridge Medical Center
Lyncburg, Virginia, United States
MeSH Terms
Interventions
Study Officials
- PRINCIPAL INVESTIGATOR
Cleveland Clinic
Cleveland Clinic Weston, FL
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 16, 2011
First Posted
May 18, 2011
Study Start
July 1, 2011
Primary Completion
June 1, 2012
Study Completion
June 1, 2012
Last Updated
January 28, 2014
Record last verified: 2012-07